Richard Stanley Bedlack | Scholars@Duke

Richard Stanley Bedlack
Professor of Neurology

1. Investigator-initiated and multi-center clinical trials testing new treatments for amyotrophic lateral sclerosis and diabetic neuropathy.

2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.

3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.

Current Appointments & Affiliations

Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2018
Faculty Network Member of the Duke Institute for Brain Sciences, Duke Institute for Brain Sciences, University Institutes and Centers 2011
Associate of the Duke Initiative for Science & Society, Duke Science & Society, Initiatives 2017

Contact Information

932 Morreene Rd Room234, Durham, NC 27705
Duke Box 3333, Durham, NC 27710
bedla001@mc.duke.edu (919) 668-2839

Background
Education, Training, & Certifications
- EMG Fellow, Medicine, Duke University 1999 - 2000
- Neurology Resident, Medicine, Duke University 1996 - 1999
- Medical Intern, Medicine, Duke University 1995 - 1996
- M.D., University of Connecticut 1995
- Ph.D., University of Connecticut 1995
Duke Appointment History
- Associate Professor of Neurology, Neurology, Neuromuscular Disease, Neurology 2011 - 2017
- Associate Professor of Medicine, Neurology, Clinical Science Departments 2006 - 2010
- Assistant Professor of Medicine, Neurology, Clinical Science Departments 2002 - 2006
- Associate in the Department of Medicine, Neurology, Clinical Science Departments 2000 - 2002
- Instructor, Temporary in the Department of Medicine, Neurology, Clinical Science Departments 2000
Recognition
In the News
- JAN 21, 2021 School of Medicine Magnify
  
  A Bold Approach to Caring for ALS Patients
- NOV 17, 2017 Duke Magazine
  
  Optimism and Sartorial Style in a Quest to Cure ALS Patients
- MAY 23, 2017 Clinical Practice Today
  
  ALS Trials Redesigned With Patient-Centric Approach
- MAR 8, 2017 Duke Health News
  
  A Symbol of Hope: How a Duke Doctor Inspired a Fashion Designer to Fight ALS
- OCT 24, 2016 NPRs All Things Considered
  
  Simplified study aims to quickly test a long-shot ALS treatment
- JUN 15, 2016 The Wall Street Journal
  
  Dr. Richard Bedlack probes the mystery of ALS patients who see improvement
- NOV 16, 2015 The News & Observer
  
  Tar Heel of the Week: Duke doctor collecting new ideas to fight ALS
- AUG 13, 2015
  
  Duke ALS Clinic Ice Bucket Challenge 2015
- AUG 13, 2015 ABC 11
  
  Ice Bucket Challenge begins at Duke ALS Clinic and the race for a cure is on
- AUG 13, 2015 Durham Herald-Sun
  
  ‘ALS is a tough disease’
- FEB 20, 2015 WTVD
  
  New discovery made about ALS could lead to a cure
- NOV 18, 2014
  
  Bedlack named to new national consortium to advance the treatment of Lou Gehrig’s disease
- AUG 29, 2014
  
  It Can Get Better
- APR 23, 2014 Ivanhoe Broadcast News
  
  Giving Jan a voice: Thinking cap for ALS
- MAR 10, 2014 The News & Observer
  
  Dr. Rick Bedlack on the challenges of treating veterans with ALS
Research
Selected Grants
- Healey ALS Platform Trial Open Label Extension Zilucoplan awarded by Massachusetts General Hospital 2020 - 2023
- A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS awarded by MediciNova, INC. 2020 - 2022
- Potential Role of the Gut Microbiome in ALS Progression and Reversals awarded by Augie's Quest to Cure ALS 2021 - 2022
- Potential Role of the Gut Microbiome in ALS Progression awarded by Martha Olson-Fernandez Foundation 2021 - 2022
- ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association 2021 - 2022
- The Duke ALS Association Certified Center awarded by Amyotrophic Lateral Sclerosis Association 2018 - 2022
- I AM ALS awarded by Massachusetts General Hospital 2021
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami 2019 - 2021
- EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002 awarded by Orion Corporation 2019 - 2021
- ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association 2020 - 2021
- Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS) awarded by Affinergy, LLC 2020
- A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS) awarded by Ultragenyx Pharmaceutical 2018 - 2020
- Duke ALS Telemedicine Clinic awarded by Amyotrophic Lateral Sclerosis Association 2018 - 2020
- Integrated Genomics in Clinical ALS (GTAC) awarded by Columbia University 2016 - 2019
- Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) awarded by Cytokinetics, Inc. 2017 - 2019
- Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami 2014 - 2019
- A Phase 2 Pharmacodynamic Study of Ezogabine on Neuronal Excitability in Amyotrophic Lateral Sclerosis awarded by GlaxoSmithKline 2015 - 2018
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation awarded by Neuraltus Pharmaceuticals, Inc 2016 - 2018
- A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031) awarded by Cytokinetics, Inc. 2016 - 2018
- A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerabiliity and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis ( ALS) awarded by Cytokinetics, Inc. 2015 - 2018
- HDE Post-Approval Study (PAS) of NeuRx DPS for ALS awarded by Synapse Biomedical, Inc 2013 - 2018
External Relationships
- AB Science
- ALS Association
- Adept Field Solutions
- Alexion
- Amylyx
- Apellis Pharmaceuticals
- Biogen Idec Inc.
- Brainstorm Cell
- Clearview Health Partners
- Clene Nanomedicine
- Corcept Therapeutics
- Cytokinetics, Inc.
- Genieus
- Guidepoint Global
- Health Advances
- ITF Pharma
- MJH Healthcare holdings
- Maple Health Care Group
- National Association of Managed Care Physicians
- New Biotic Inc
- Orphazyme
- Projects in Knowledge
- The CM Group
- UCB Pharma
- WebMD health
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Choi, P. J., M. Murn, R. Turner, and R. Bedlack. “Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible (Accepted).” American Journal of Hospice and Palliative Medicine 38, no. 10 (October 1, 2021): 1238–41. https://doi.org/10.1177/1049909120982291.
    Full Text
  - Cudkowicz, M., A. Genge, N. Maragakis, S. Petri, L. van den Berg, V. V. Aho, T. Sarapohja, et al. “Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial (Accepted).” The Lancet Neurology 20, no. 10 (October 1, 2021): 821–31. https://doi.org/10.1016/S1474-4422(21)00242-8.
    Full Text
  - Galea, Marinella D., Vincent P. Galea, Adam C. Eberhart, Huned S. Patwa, Ileana Howard, Christina N. Fournier, and Richard S. Bedlack. “Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19.” Muscle Nerve 64, no. 4 (October 2021): E18–20. https://doi.org/10.1002/mus.27373.
    Full Text Link to Item
  - Li, Xiaoyan, and Richard Bedlack. “COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis.” Muscle & Nerve 64, no. 3 (September 2021): E13–15. https://doi.org/10.1002/mus.27351.
    Full Text
  - Mahoney, Colin J., Rebekah M. Ahmed, William Huynh, Sicong Tu, Jonathan D. Rohrer, Richard S. Bedlack, Orla Hardiman, and Matthew C. Kiernan. “Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.” Cns Drugs 35, no. 5 (May 2021): 483–505. https://doi.org/10.1007/s40263-021-00820-1.
    Full Text Link to Item
  - ALSUNTANGLED GROUP, Majid. “ALSUntangled 57: Vinpocetine.” Amyotroph Lateral Scler Frontotemporal Degener 22, no. 3–4 (May 2021): 316–19. https://doi.org/10.1080/21678421.2020.1786942.
    Full Text Link to Item
  - Wainger, Brian J., Eric A. Macklin, Steve Vucic, Courtney E. McIlduff, Sabrina Paganoni, Nicholas J. Maragakis, Richard Bedlack, et al. “Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.” Jama Neurol 78, no. 2 (February 1, 2021): 186–96. https://doi.org/10.1001/jamaneurol.2020.4300.
    Full Text Link to Item
  - Berry, James D., Richard Bedlack, Debra Mathews, Wendy Agnese, and Stephen Apple. “Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study.” Amyotroph Lateral Scler Frontotemporal Degener 22, no. 1–2 (February 2021): 147–50. https://doi.org/10.1080/21678421.2020.1804939.
    Full Text Link to Item
  - Crayle, Jesse, Mai Elmallah, John Sleasman, and Richard Bedlack. “Total serum immunoglobulin A in ALS.” Amyotroph Lateral Scler Frontotemporal Degener 22, no. 1–2 (February 2021): 61–65. https://doi.org/10.1080/21678421.2020.1790608.
    Full Text Link to Item
  - Bedlack, Richard, Sky Kihuwa-Mani, Paul E. Barkhaus, Michael Bereman, James B. Caress, Jesse Crayle, Gary L. Pattee, et al. “ALSUntangled 59: Tamoxifen.” Amyotroph Lateral Scler Frontotemporal Degener, January 21, 2021, 1–4. https://doi.org/10.1080/21678421.2021.1876731.
    Full Text Link to Item
  - Bedlack, R., P. Barkhaus, B. Barnes, M. Bereman, T. Bertorini, G. Carter, J. Crayle, et al. “ALSUntangled #60: light therapy.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, January 1, 2021. https://doi.org/10.1080/21678421.2021.1883668.
    Full Text
  - Bedlack, R., S. Appel, P. Barkhaus, T. Bertorini, M. Bromberg, G. Carter, J. Crayle, et al. “ALSUntangled #61: melatonin.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, January 1, 2021. https://doi.org/10.1080/21678421.2021.1927103.
    Full Text
  - Theunissen, Frances, Ryan S. Anderton, Frank L. Mastaglia, Loren L. Flynn, Samantha J. Winter, Ian James, Richard Bedlack, et al. “Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype.” Frontiers in Aging Neuroscience 13 (January 2021): 658226. https://doi.org/10.3389/fnagi.2021.658226.
    Full Text
  - Saez-Atienzar, Sara, Clifton L. Dalgard, Jinhui Ding, Adriano Chiò, Camile Alba, Dan N. Hupalo, Matthew D. Wilkerson, et al. “Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred.” Neurology 95, no. 22 (December 1, 2020): 1015–18. https://doi.org/10.1212/WNL.0000000000011064.
    Full Text Link to Item
  - ALSUntangled Group, Debra L. “ALSUntangled 56: "ten red flags"-things to be wary of in alternative or off-label products.” Amyotroph Lateral Scler Frontotemporal Degener 21, no. 7–8 (November 2020): 642–47. https://doi.org/10.1080/21678421.2020.1765518.
    Full Text Link to Item
  - Andrews, Jinsy A., James D. Berry, Robert H. Baloh, Nathan Carberry, Merit E. Cudkowicz, Brixhilda Dedi, Jonathan Glass, et al. “Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.” Muscle Nerve 62, no. 2 (August 2020): 182–86. https://doi.org/10.1002/mus.26989.
    Full Text Link to Item
  - Pytte, Julia, Loren L. Flynn, Ryan S. Anderton, Frank L. Mastaglia, Frances Theunissen, Ian James, Abigail Pfaff, et al. “Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort.” Neurol Genet 6, no. 4 (August 2020): e470. https://doi.org/10.1212/NXG.0000000000000470.
    Full Text Link to Item
  - Brizzi, Kate T., John F. P. Bridges, Jill Yersak, Calaneet Balas, Neil Thakur, Miriam Galvin, Orla Hardiman, et al. “Understanding the needs of people with ALS: a national survey of patients and caregivers.” Amyotroph Lateral Scler Frontotemporal Degener 21, no. 5–6 (August 2020): 355–63. https://doi.org/10.1080/21678421.2020.1760889.
    Full Text Link to Item
  - Bedlack, Richard, Allison Pogemiller, Jeremy Shefner, Merit Cudkowicz, and Terri Heiman-Patterson. “ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.” Amyotroph Lateral Scler Frontotemporal Degener 21, no. 3–4 (May 2020): 216–21. https://doi.org/10.1080/21678421.2019.1690519.
    Full Text Link to Item
  - Mitsumoto, Hiroshi, Diana C. Garofalo, Regina M. Santella, Eric J. Sorenson, Björn Oskarsson, J Americo M. Fernandes, Howard Andrews, et al. “Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.” Amyotroph Lateral Scler Frontotemporal Degener 21, no. 3–4 (May 2020): 263–72. https://doi.org/10.1080/21678421.2020.1746810.
    Full Text Link to Item
  - Fournier, Christina N., Richard Bedlack, Colin Quinn, James Russell, Diane Beckwith, Kathleen H. Kaminski, William Tyor, et al. “Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).” Jama Neurol 77, no. 4 (April 1, 2020): 480–88. https://doi.org/10.1001/jamaneurol.2019.4490.
    Full Text Link to Item
  - Pytte, Julia, Ryan S. Anderton, Loren L. Flynn, Frances Theunissen, Leanne Jiang, Ianthe Pitout, Ian James, et al. “Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis.” Neurol Genet 6, no. 2 (April 2020): e406. https://doi.org/10.1212/NXG.0000000000000406.
    Full Text Link to Item
  - Urbi, Berzenn, Simon Broadley, Richard Bedlack, Ethan Russo, and Arman Sabet. “Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.” Bmj Open 9, no. 11 (November 11, 2019): e029449. https://doi.org/10.1136/bmjopen-2019-029449.
    Full Text Link to Item
  - Bedlack, Rick. “ALSUntangled 48: Perampanel (Fycompa).” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 5–6 (August 2019): 453–56. https://doi.org/10.1080/21678421.2019.1573850.
    Full Text Link to Item
  - Bedlack, R. S., Paul Wicks, Timothy Vaughan, Alicia Opie, Rebecca Blum, Amanda Dios, and Ghazaleh Sadri-Vakili. “Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 3–4 (May 2019): 285–93. https://doi.org/10.1080/21678421.2018.1556698.
    Full Text Link to Item
  - Bedlack, Richard. “ALSUntangled No. 47: RT001.” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 3–4 (May 2019): 294–97. https://doi.org/10.1080/21678421.2018.1549531.
    Full Text Link to Item
  - ALSUntangled Group, Richard, and Richard Bedlack. “ALSUntangled 46: penicillin G/hydrocortisone.” Amyotroph Lateral Scler Frontotemporal Degener 20, no. 1–2 (February 2019): 126–31. https://doi.org/10.1080/21678421.2018.1512704.
    Full Text Link to Item
  - Statland, Jeffrey M., Dan Moore, Yunxia Wang, Maureen Walsh, Tahseen Mozaffar, Lauren Elman, Sharon P. Nations, et al. “Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.” Muscle Nerve 59, no. 2 (February 2019): 201–7. https://doi.org/10.1002/mus.26335.
    Full Text Link to Item
  - Woolley, Susan, Ray Goetz, Pam Factor-Litvak, Jennifer Murphy, Jonathan Hupf, Diana C. Garofalo, Catherine Lomen-Hoerth, et al. “Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients".” Behav Neurol 2019 (2019): 6704740. https://doi.org/10.1155/2019/6704740.
    Full Text Link to Item
  - Bedlack, Richard, and Richard ALSUntangled Group. “ALSUntangled 44: curcumin.” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 7–8 (November 2018): 623–29. https://doi.org/10.1080/21678421.2018.1440738.
    Full Text Link to Item
  - Harrison, Daniel, Paul Mehta, Michael A. van Es, Elijah Stommel, Vivian E. Drory, Beatrice Nefussy, Leonard H. van den Berg, Jesse Crayle, Richard Bedlack, and Richard Pooled Resource Open-Access ALS Clinical Trials Consortium. “"ALS reversals": demographics, disease characteristics, treatments, and co-morbidities.” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 7–8 (November 2018): 495–99. https://doi.org/10.1080/21678421.2018.1457059.
    Full Text Link to Item
  - ALSUNTANGLED GROUP, N. A. N. C. Y. “ALSUntangled 43: copper.” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 5–6 (August 2018): 472–76. https://doi.org/10.1080/21678421.2017.1406733.
    Full Text Link to Item
  - Wolpaw, Jonathan R., Richard S. Bedlack, Domenic J. Reda, Robert J. Ringer, Patricia G. Banks, Theresa M. Vaughan, Susan M. Heckman, et al. “Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis.” Neurology 91, no. 3 (July 17, 2018): e258–67. https://doi.org/10.1212/WNL.0000000000005812.
    Full Text Link to Item
  - Bedlack, Richard, and Richard ALSUntangled Group. “ALSUntangled 42: Elysium health's "basis".” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 3–4 (May 2018): 317–19. https://doi.org/10.1080/21678421.2017.1373978.
    Full Text Link to Item
  - Earl, Damien E., Aaron I. Loochtan, and Richard S. Bedlack. “Refractory myasthenia gravis exacerbation triggered By pembrolizumab.” Muscle Nerve 57, no. 4 (April 2018): E120–21. https://doi.org/10.1002/mus.26021.
    Full Text Link to Item
  - Nicolas, Aude, Kevin P. Kenna, Alan E. Renton, Nicola Ticozzi, Faraz Faghri, Ruth Chia, Janice A. Dominov, et al. “Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.” Neuron 97, no. 6 (March 21, 2018): 1268-1283.e6. https://doi.org/10.1016/j.neuron.2018.02.027.
    Full Text Link to Item
  - ALSUntangled Group, C. R. N. “ALSUntangled 41: "Eric Is Winning".” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 1–2 (February 2018): 157–60. https://doi.org/10.1080/21678421.2017.1350532.
    Full Text Link to Item
  - Horton, D Kevin, Shannon Graham, Reshma Punjani, Grete Wilt, Wendy Kaye, Kimberly Maginnis, Lauren Webb, et al. “A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013.” Amyotroph Lateral Scler Frontotemporal Degener 19, no. 1–2 (February 2018): 126–33. https://doi.org/10.1080/21678421.2017.1406953.
    Full Text Link to Item
  - Woolley, Susan, Ray Goetz, Pam Factor-Litvak, Jennifer Murphy, Jonathan Hupf, Diana C. Garofalo, Catherine Lomen-Hoerth, et al. “Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients.” Behav Neurol 2018 (2018): 5969137. https://doi.org/10.1155/2018/5969137.
    Full Text Link to Item
  - Bedlack, Richard. “Perspective: Untangling the ALS X-Files.” Nature 550, no. 7676 (October 18, 2017): S122. https://doi.org/10.1038/550S122a.
    Full Text Link to Item
  - ALSUntangled Group, Alexander. “ALSUntangled No. 37: Inosine.” Amyotroph Lateral Scler Frontotemporal Degener 18, no. 3–4 (May 2017): 309–12. https://doi.org/10.1080/21678421.2016.1223270.
    Full Text Link to Item
  - ALSUNTANGLED GROUP, H. “ALSUntangled No. 36: Accilion.” Amyotroph Lateral Scler Frontotemporal Degener 18, no. 1–2 (February 2017): 142–47. https://doi.org/10.1080/21678421.2016.1215400.
    Full Text Link to Item
  - ALSUntangled Group, Hiroshi. “ALSUntangled 38: L-serine.” Amyotroph Lateral Scler Frontotemporal Degener 18, no. 1–2 (February 2017): 148–51. https://doi.org/10.1080/21678421.2016.1250353.
    Full Text Link to Item
  - Mukherjee, Nisha, Shan McBurney-Lin, Anthony Kuo, Richard Bedlack, and Henry Tseng. “Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease.” Plos One 12, no. 9 (2017): e0185242. https://doi.org/10.1371/journal.pone.0185242.
    Full Text Link to Item
  - Nieves, Jeri W., Chris Gennings, Pam Factor-Litvak, Jonathan Hupf, Jessica Singleton, Valerie Sharf, Björn Oskarsson, et al. “Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.” Jama Neurol 73, no. 12 (December 1, 2016): 1425–32. https://doi.org/10.1001/jamaneurol.2016.3401.
    Full Text Link to Item
  - ALSUntangled Group, Epi4K. “ALSUntangled No. 35: Hyperbaric Oxygen Therapy.” Amyotroph Lateral Scler Frontotemporal Degener 17, no. 7–8 (October 2016): 622–24. https://doi.org/10.3109/21678421.2016.1172818.
    Full Text Link to Item
  - “ALSUntangled No. 34: GM604.” Amyotroph Lateral Scler Frontotemporal Degener 17, no. 7–8 (October 2016): 617–21. https://doi.org/10.3109/21678421.2016.1164940.
    Full Text Link to Item
  - Lee, Caroline M., Jason D. Lee, Lisa D. Hobson-Webb, Richard S. Bedlack, and Joseph K. Salama. “Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report.” Ann Intern Med 165, no. 4 (August 16, 2016): 300–301. https://doi.org/10.7326/L15-0469.
    Full Text Link to Item
  - Bedlack, Richard S., Timothy Vaughan, Paul Wicks, Jamie Heywood, Ervin Sinani, Roger Selsov, Eric A. Macklin, David Schoenfeld, Merit Cudkowicz, and Alex Sherman. “How common are ALS plateaus and reversals?” Neurology 86, no. 9 (March 1, 2016): 808–12. https://doi.org/10.1212/WNL.0000000000002251.
    Full Text Link to Item
  - Murphy, Jennifer, Pam Factor-Litvak, Raymond Goetz, Catherine Lomen-Hoerth, Peter L. Nagy, Jonathan Hupf, Jessica Singleton, et al. “Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.” Neurology 86, no. 9 (March 1, 2016): 813–20. https://doi.org/10.1212/WNL.0000000000002305.
    Full Text Link to Item
  - Karam, Chafic Y., Sabrina Paganoni, Nanette Joyce, Gregory T. Carter, and Richard Bedlack. “Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.” Am J Hosp Palliat Care 33, no. 1 (February 2016): 84–92. https://doi.org/10.1177/1049909114548719.
    Full Text Link to Item
  - Bedlack, Richard S., Nanette Joyce, Gregory T. Carter, Sabrina Paganoni, and Chafic Karam. “Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.” Neurol Clin 33, no. 4 (November 2015): 909–36. https://doi.org/10.1016/j.ncl.2015.07.008.
    Full Text Link to Item
  - Miller, Robert G., Gilbert Block, Jonathan S. Katz, Richard J. Barohn, Vidhya Gopalakrishnan, Merit Cudkowicz, Jane R. Zhang, et al. “Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.” Neurol Neuroimmunol Neuroinflamm 2, no. 3 (June 2015): e100. https://doi.org/10.1212/NXI.0000000000000100.
    Full Text Link to Item
  - Cirulli, Elizabeth T., Brittany N. Lasseigne, Slavé Petrovski, Peter C. Sapp, Patrick A. Dion, Claire S. Leblond, Julien Couthouis, et al. “Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.” Science 347, no. 6229 (March 27, 2015): 1436–41. https://doi.org/10.1126/science.aaa3650.
    Full Text Link to Item
  - ALSUntangled Group, Jesus. “ALSUntangled: introducing The Table of Evidence.” Amyotroph Lateral Scler Frontotemporal Degener 16, no. 1–2 (March 2015): 142–45. https://doi.org/10.3109/21678421.2014.987476.
    Full Text Link to Item
  - ALSUntangled Group, F. “ALSUntangled No. 29: MitoQ.” Amyotroph Lateral Scler Frontotemporal Degener 16, no. 5–6 (2015): 427–29. https://doi.org/10.3109/21678421.2015.1050897.
    Full Text Link to Item
  - Paganoni, Sabrina, Chafic Karam, Nanette Joyce, Richard Bedlack, and Gregory T. Carter. “Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.” Neurorehabilitation 37, no. 1 (2015): 53–68. https://doi.org/10.3233/NRE-151240.
    Full Text Link to Item
  - ALSUntangled Group, J. “ALSUntangled No. 26: lunasin.” Amyotroph Lateral Scler Frontotemporal Degener 15, no. 7–8 (December 2014): 622–26. https://doi.org/10.3109/21678421.2014.959297.
    Full Text Link to Item
  - Mitsumoto, Hiroshi, Pam Factor-Litvak, Howard Andrews, Raymond R. Goetz, Leslie Andrews, Judith G. Rabkin, Martin McElhiney, et al. “ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.” Amyotroph Lateral Scler Frontotemporal Degener 15, no. 3–4 (June 2014): 192–203. https://doi.org/10.3109/21678421.2013.864312.
    Full Text Link to Item
  - Rabourn, Jess, and Richard S. Bedlack. “SAPs: a different perspective.” Am J Bioeth 14, no. 11 (2014): 19–20. https://doi.org/10.1080/15265161.2014.957621.
    Full Text Link to Item
  - ALSUntangled Group, Eric, Christina Fournier, Bedlack Bedlack, Orla Hardiman, Terry Heiman-Patterson, Laurie Gutmann, Mark Bromberg, et al. “ALS Untangled No. 20: the Deanna protocol.” Amyotroph Lateral Scler Frontotemporal Degener 14, no. 4 (May 2013): 319–23. https://doi.org/10.3109/21678421.2013.788405.
    Full Text Link to Item
  - Chad, David A., Lewis P. Rowland, Carmel Armon, Richard Bedlack, Heather Durham, Pam Factor-Litvak, Terry Heiman-Patterson, et al. “Peer recommendations on how to improve clinical research, and Conference wrap-up.” Amyotroph Lateral Scler Frontotemporal Degener 14 Suppl 1 (May 2013): 67–73. https://doi.org/10.3109/21678421.2013.778605.
    Full Text Link to Item
  - Sherman, Alexander V., Amelie K. Gubitz, Ammar Al-Chalabi, Richard Bedlack, James Berry, Robin Conwit, Brent T. Harris, et al. “Infrastructure resources for clinical research in amyotrophic lateral sclerosis.” Amyotroph Lateral Scler Frontotemporal Degener 14 Suppl 1 (May 2013): 53–61. https://doi.org/10.3109/21678421.2013.779058.
    Full Text Link to Item
  - Pastula, Daniel M., Dan H. Moore, and Richard S. Bedlack. “Creatine for amyotrophic lateral sclerosis/motor neuron disease.” Cochrane Database Syst Rev 12 (December 12, 2012): CD005225. https://doi.org/10.1002/14651858.CD005225.pub3.
    Full Text Link to Item
  - ALSUntangled Group, Hans H. “ALS untangled No. 17: "when ALS is lyme".” Amyotroph Lateral Scler 13, no. 5 (September 2012): 487–91. https://doi.org/10.3109/17482968.2012.717796.
    Full Text Link to Item
  - Scherer, Katalin, and Richard S. Bedlack. “Diaphragm pacing in amyotrophic lateral sclerosis: a literature review.” Muscle Nerve 46, no. 1 (July 2012): 1–8. https://doi.org/10.1002/mus.23419.
    Full Text Link to Item
  - ALSUntangled Group, DASH Res. “ALSUntangled No. 16: cannabis.” Amyotroph Lateral Scler 13, no. 4 (June 2012): 400–404. https://doi.org/10.3109/17482968.2012.687264.
    Full Text Link to Item
  - Kamel, Freya, David M. Umbach, Richard S. Bedlack, Marie Richards, Mary Watson, Michael C. R. Alavanja, Aaron Blair, Jane A. Hoppin, Silke Schmidt, and Dale P. Sandler. “Pesticide exposure and amyotrophic lateral sclerosis.” Neurotoxicology 33, no. 3 (June 2012): 457–62. https://doi.org/10.1016/j.neuro.2012.04.001.
    Full Text Link to Item
  - ALSUntangled Group, J. T. “ALSUntangled 15: coconut Oil.” Amyotroph Lateral Scler 13, no. 3 (May 2012): 328–30. https://doi.org/10.3109/17482968.2012.671629.
    Full Text Link to Item
  - Caulfield, Timothy, Amy Zarzeczny, and Amy Toronto Stem Cell Working Group. “Stem cell tourism and Canadian family physicians.” Can Fam Physician 58, no. 4 (April 2012): 365-e185.
    Link to Item
  - Donofrio, Peter D., and Richard Bedlack. “Historical controls in ALS trials: a high seas rescue?” Neurology 77, no. 10 (September 6, 2011): 936–37. https://doi.org/10.1212/WNL.0b013e31822cfcb6.
    Full Text Link to Item
  - Bedlack, Richard S. “Compassionate use of stem cells for ALS: popovers and hot air.” Amyotroph Lateral Scler 12, no. 5 (September 2011): 313–14. https://doi.org/10.3109/17482968.2011.583743.
    Full Text Link to Item
  - Bedlack, Richard S., Angela Genge, Anthony A. Amato, Aziz Shaibani, Carlayne E. Jackson, John T. Kissel, Cheryl Wall, et al. “Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.” J Neuropathol Exp Neurol 70, no. 1 (January 2011): 96–97. https://doi.org/10.1097/NEN.0b013e318204782b.
    Full Text Link to Item
  - Simmons, Bryan J., Todd J. Cohen, Richard Bedlack, and Tso-Pang Yao. “HDACs in skeletal muscle remodeling and neuromuscular disease.” Handb Exp Pharmacol 206 (2011): 79–101. https://doi.org/10.1007/978-3-642-21631-2_5.
    Full Text Link to Item
  - Bedlack, Richard S., Paul Wicks, James Heywood, and Edward Kasarskis. “Modifiable barriers to enrollment in American ALS research studies.” Amyotroph Lateral Scler 11, no. 6 (December 2010): 502–7. https://doi.org/10.3109/17482968.2010.484494.
    Full Text Link to Item
  - Bedlack, Richard S. “Amyotrophic lateral sclerosis: current practice and future treatments.” Curr Opin Neurol 23, no. 5 (October 2010): 524–29. https://doi.org/10.1097/WCO.0b013e32833c7ac2.
    Full Text Link to Item
  - Schellenberg, Kerri, Richard Bedlack, and Debara Tucci. “Roaring in the ears: patulous Eustachian tube in bulbar amyotrophic lateral sclerosis.” Amyotroph Lateral Scler 11, no. 4 (August 2010): 395–96. https://doi.org/10.3109/17482960903501931.
    Full Text Link to Item
  - Pastula, Daniel M., Dan H. Moore, and Richard S. Bedlack. “Creatine for amyotrophic lateral sclerosis/motor neuron disease.” Cochrane Database Syst Rev, no. 6 (June 16, 2010): CD005225. https://doi.org/10.1002/14651858.CD005225.pub2.
    Full Text Link to Item
  - Khishchenko, Natan, Kelli D. Allen, Cynthia J. Coffman, Edward J. Kasarskis, Jennifer H. Lindquist, Joel C. Morgenlander, Barbara B. Norman, et al. “Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis.” Amyotroph Lateral Scler 11, no. 1–2 (2010): 125–32. https://doi.org/10.3109/17482960802572681.
    Full Text Link to Item
  - Pastula, Daniel M., Cynthia J. Coffman, Kelli D. Allen, Eugene Z. Oddone, Edward J. Kasarskis, Jennifer H. Lindquist, Joel C. Morgenlander, et al. “Factors associated with survival in the National Registry of Veterans with ALS.” Amyotroph Lateral Scler 10, no. 5–6 (October 2009): 332–38. https://doi.org/10.3109/17482960802320545.
    Full Text Link to Item
  - Qureshi, Muddasir, Richard S. Bedlack, and Merit E. Cudkowicz. “Lyme disease serology in amyotrophic lateral sclerosis.” Muscle Nerve 40, no. 4 (October 2009): 626–28. https://doi.org/10.1002/mus.21438.
    Full Text Link to Item
  - Bedlack, Richard S., Daniel M. Pastula, Jodi Hawes, and Debra Heydt. “Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.” Amyotroph Lateral Scler 10, no. 4 (August 2009): 210–15. https://doi.org/10.1080/17482960802430773.
    Full Text Link to Item
  - Bedlack, Richard S., Vincenzo Silani, and Merit Ester Cudkowicz. “IPLEX and the telephone game: the difficulty in separating myth from reality on the internet.” Amyotroph Lateral Scler 10, no. 3 (June 2009): 182–84. https://doi.org/10.1080/17482960802673059.
    Full Text Link to Item
  - Bedlack, Richard, and Orla Hardiman. “ALSUntangled (ALSU): a scientific approach to off-label treatment options for people with ALS using tweets and twitters.” Amyotroph Lateral Scler 10, no. 3 (June 2009): 129–30. https://doi.org/10.1080/17482960903015986.
    Full Text Link to Item
  - Cudkowicz, Merit E., Patricia L. Andres, Sally A. Macdonald, Richard S. Bedlack, Rabia Choudry, Robert H. Brown, Hui Zhang, et al. “Phase 2 study of sodium phenylbutyrate in ALS.” Amyotroph Lateral Scler 10, no. 2 (April 2009): 99–106. https://doi.org/10.1080/17482960802320487.
    Full Text Link to Item
  - Bedlack, R. S., and S. Aggarwal. “Als update: Signs of progress, easons for hope.” Continuum Lifelong Learning in Neurology 15, no. 1 (January 1, 2009): 83–110. https://doi.org/10.1212/01.CON.0000300009.02717.a2.
    Full Text
  - Bedlack, Richard S., and Merit E. Cudkowicz. “Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance.” Front Neurol Neurosci 25 (2009): 144–51. https://doi.org/10.1159/000209493.
    Full Text Link to Item
  - Bedlack, Richard S., Daniel M. Pastula, Emily Welsh, Darlene Pulley, and Merit E. Cudkowicz. “Scrutinizing enrollment in ALS clinical trials: room for improvement?” Amyotroph Lateral Scler 9, no. 5 (October 2008): 257–65. https://doi.org/10.1080/17482960802195913.
    Full Text Link to Item
  - Rosenfeld, Jeffrey, Ruth M. King, Carlayne E. Jackson, Richard S. Bedlack, Richard J. Barohn, Arthur Dick, Lawrence H. Phillips, John Chapin, Deborah F. Gelinas, and Jau-Shin Lou. “Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.” Amyotroph Lateral Scler 9, no. 5 (October 2008): 266–72. https://doi.org/10.1080/17482960802028890.
    Full Text Link to Item
  - Gordon, Paul H., Ying-Kuen Cheung, Bruce Levin, Howard Andrews, Carolyn Doorish, Robert B. Macarthur, Jacqueline Montes, et al. “A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.” Amyotroph Lateral Scler 9, no. 4 (August 2008): 212–22. https://doi.org/10.1080/17482960802195632.
    Full Text Link to Item
  - Bedlack, Richard S., Nicholas Maragakis, and Terry Heiman-Patterson. “Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed.” Proc Natl Acad Sci U S A 105, no. 16 (April 22, 2008): E17. https://doi.org/10.1073/pnas.0801762105.
    Full Text Link to Item
  - Allen, K. D., E. J. Kasarskis, R. S. Bedlack, M. P. Rozear, J. C. Morgenlander, A. Sabet, L. Sams, et al. “The National Registry of Veterans with amyotrophic lateral sclerosis.” Neuroepidemiology 30, no. 3 (2008): 180–90. https://doi.org/10.1159/000126910.
    Full Text Link to Item
  - Schmidt, Silke, Kelli D. Allen, Valerie T. Loiacono, Barbara Norman, Catherine L. Stanwyck, Kristina M. Nord, Christina D. Williams, et al. “Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.” Neuroepidemiology 30, no. 3 (2008): 191–204. https://doi.org/10.1159/000126911.
    Full Text Link to Item
  - Gwinn, Katrina, Roderick A. Corriveau, Hiroshi Mitsumoto, Kate Bednarz, Robert H. Brown, Merit Cudkowicz, Paul H. Gordon, et al. “Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery.” Plos One 2, no. 12 (December 5, 2007): e1254. https://doi.org/10.1371/journal.pone.0001254.
    Full Text Link to Item
  - Gordon, Paul H., Dan H. Moore, Robert G. Miller, Julaine M. Florence, Joseph L. Verheijde, Carolyn Doorish, Joan F. Hilton, et al. “Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.” Lancet Neurol 6, no. 12 (December 2007): 1045–53. https://doi.org/10.1016/S1474-4422(07)70270-3.
    Full Text Link to Item
  - Bedlack, Richard S., Bryan J. Traynor, and Merit E. Cudkowicz. “Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis.” Expert Opin Emerg Drugs 12, no. 2 (May 2007): 229–52. https://doi.org/10.1517/14728214.12.2.229.
    Full Text Link to Item
  - Tabbarah, Khalid, John Madden, and Richard S. Bedlack. “Dysarthria and dysphagia from light chain amyloidosis.” Neurology 65, no. 10 (November 22, 2005): 1671. https://doi.org/10.1212/01.wnl.0000182295.32791.e5.
    Full Text Link to Item
  - Scherer, K., and R. S. Bedlack. “Working through the challenges of neuropathic pain.” Emergency Medicine 37, no. 10 (October 1, 2005): 37–43.
  - Bedlack, R. S., D. L. Simel, H. Bosworth, G. Samsa, B. Tucker-Lipscomb, and D. B. Sanders. “Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.” Neurology 64, no. 11 (June 14, 2005): 1968–70. https://doi.org/10.1212/01.WNL.0000163988.28892.79.
    Full Text Link to Item
  - Scherer, Katalin, Richard S. Bedlack, and David L. Simel. “Does this patient have myasthenia gravis?” Jama 293, no. 15 (April 20, 2005): 1906–14. https://doi.org/10.1001/jama.293.15.1906.
    Full Text Link to Item
  - Bedlack, Richard S., Tuan Vu, Simon Hammans, Steven A. Sparr, Bennett Myers, Joel Morgenlander, and Michio Hirano. “MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy.” Muscle Nerve 29, no. 3 (March 2004): 364–68. https://doi.org/10.1002/mus.10546.
    Full Text Link to Item
  - Burke, P., and R. S. Bedlack. “Diagnosing and stabilizing acute neuropathies.” Emergency Medicine 36, no. 1 (January 1, 2004): 15–27.
  - Bedlack, R. S., D. Edelman, J. W. Gibbs, D. Kelling, W. Strittmatter, A. M. Saunders, and J. Morgenlander. “APOE genotype is a risk factor for neuropathy severity in diabetic patients.” Neurology 60, no. 6 (March 25, 2003): 1022–24. https://doi.org/10.1212/01.wnl.0000056689.50682.94.
    Full Text Link to Item
  - Brewer, R., R. Bedlack, and E. Massey. “Erratum: Diabetic thoracic radiculopathy: An unusual cause of post-thoracotomy pain (Pain (2003) 105 (221-223)).” Pain 105, no. 3 (January 1, 2003): 509. https://doi.org/10.1016/j.pain.2003.09.001.
    Full Text
  - Armon, Carmel, Roberto J. Guiloff, and Richard Bedlack. “Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.” Amyotroph Lateral Scler Other Motor Neuron Disord 3, no. 3 (September 2002): 109–12. https://doi.org/10.1080/146608202760834094.
    Full Text Link to Item
  - Bedlack, Richard S., and Donald B. Sanders. “On the concept of myasthenic crisis.” J Clin Neuromuscul Dis 4, no. 1 (September 2002): 40–42. https://doi.org/10.1097/00131402-200209000-00009.
    Full Text Link to Item
  - Bedlack, Richard S., and Donald B. Sanders. “Steroid treatment for myasthenia gravis: steroids have an important role.” Muscle Nerve 25, no. 1 (January 2002): 117–21. https://doi.org/10.1002/mus.1221.
    Full Text Link to Item
  - Bedlack, R. S., W. J. Strittmatter, and J. C. Morgenlander. “Apolipoprotein E and neuromuscular disease: a critical review of the literature.” Arch Neurol 57, no. 11 (November 2000): 1561–65. https://doi.org/10.1001/archneur.57.11.1561.
    Full Text Link to Item
  - Bedlack, R. S., T. E. Bertorini, and D. B. Sanders. “Hidden afterdischarges in slow channel congenital myasthenic syndrome.” J Clin Neuromuscul Dis 1, no. 4 (June 2000): 186–90. https://doi.org/10.1097/00131402-200006000-00005.
    Full Text Link to Item
  - Bedlack, R. S., and D. B. Sanders. “How to handle myasthenic crisis. Essential steps in patient care.” Postgrad Med 107, no. 4 (April 2000): 211–22. https://doi.org/10.3810/pgm.2000.04.1003.
    Full Text Link to Item
  - Ahearn, G. S., R. S. Bedlack, D. T. Price, C. N. Robertson, and J. C. Morgenlander. “Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis.” South Med J 92, no. 8 (August 1999): 809–11. https://doi.org/10.1097/00007611-199908000-00013.
    Full Text Link to Item
  - Verma, A., R. S. Bedlack, R. A. Radtke, K. E. VanLandingham, and C. W. Erwin. “Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study.” J Clin Neurophysiol 16, no. 1 (January 1999): 46–50. https://doi.org/10.1097/00004691-199901000-00004.
    Full Text Link to Item
  - Bedlack, R. S., M. D. Wei, S. H. Fox, E. Gross, and L. M. Loew. “Distinct electric potentials in soma and neurite membranes.” Neuron 13, no. 5 (November 1994): 1187–93. https://doi.org/10.1016/0896-6273(94)90056-6.
    Full Text Link to Item
  - Gross, E., R. S. Bedlack, and L. M. Loew. “Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential.” Biophys J 67, no. 1 (July 1994): 208–16. https://doi.org/10.1016/S0006-3495(94)80471-0.
    Full Text Link to Item
  - Bedlack, R. S., M. Wei, and L. M. Loew. “Localized membrane depolarizations and localized calcium influx during electric field-guided neurite growth.” Neuron 9, no. 3 (September 1992): 393–403. https://doi.org/10.1016/0896-6273(92)90178-g.
    Full Text Link to Item
- Conference Papers
  - Bedlack, Richard S., Daniel Pastuala, Elizabeth Welsh, Darlene Pulley, and Merit Cudkowicz. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?” In Neurology, 70:A344–A344. LIPPINCOTT WILLIAMS & WILKINS, 2008.
    Link to Item
  - Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” In Muscle & Nerve, 34:514–514. JOHN WILEY & SONS INC, 2006.
    Link to Item
  - Bedlack, R. S., D. Kelling, D. Edelman, J. W. Gibbs, W. Strittmatter, and J. Morgenlander. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” In Annals of Neurology, 52:866–866. WILEY-LISS, 2002.
    Link to Item
  - Gross, E., R. S. Bedlack, and L. M. Loew. “Fluorescent imaging of membrane potential components.” In Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, 286:249–56. PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996.
    Link to Item
  - BEDLACK, R. S., M. D. WEI, S. FOX, E. GROSS, and L. M. LOEW. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” In Biophysical Journal, 66:A387–A387. BIOPHYSICAL SOCIETY, 1994.
    Link to Item
  - GROSS, E., R. S. BEDLACK, and L. M. LOEW. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” In Biophysical Journal, 66:A387–A387. BIOPHYSICAL SOCIETY, 1994.
    Link to Item
  - BEDLACK, R. S., M. D. WEI, and L. M. LOEW. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” In Biophysical Journal, 64:A101–A101. BIOPHYSICAL SOCIETY, 1993.
    Link to Item
Teaching & Mentoring
Recent Courses
- NEUROSCI 493: Research Independent Study 1 2020

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

In the News

Selected Grants

External Relationships

Selected Publications

Academic Articles

Conference Papers

Recent Courses